GILEAD SCIENCES, INC.

GILEAD SCIENCES, INC. (GILD) — Investment Memo

🐂 The Bull Case (Warren's voice)

• The moat is durable only as long as the patent clock ticks. HIV is a chronic, sticky therapy – patients don’t switch unless forced. Biktarvy’s $11–12B revenue is a cash machine today.
• Economics are exceptional right now. Gross margins are high, FCF consistently beats net income (e.g., $9.5B FCF vs. $8.5B NI in 2025). The business throws off $8–10B of free cash yearly – a genuine cash cow, albeit a shrinking one.
• At a sufficient discount, this becomes a liquidating value play. If Biktarvy dies but the company returns capital via buybacks and dividends, a low entry price could still produce acceptable returns. The DCF suggests intrinsic value of $115.58/share – but only if you believe the terminal growth story.

🐻 The Bear Case (Charlie inverts)

• Scenario #1: The Patent Cliff (Most Likely, 2028–2030). Biktarvy’s U.S. patent expires. Generics carve 80–90% of revenue within two years. Gilead has no pipeline replacement of equal size – cell therapy and Trodelvy combined are < $4B. Revenue collapses to < $15B, FCF halves, and the moat is gone.
• Scenario #2: The Acquisition Trap. Management’s track record: $21B for Trodelvy (Immunomedics) – returns tiny. Future desperation acquisitions (e.g., another oncology bet) destroy billions more, leveraging the balance sheet and diluting remaining cash flows.
• Scenario #3: Regulatory / Pricing Shock. U.S. government or insurers demand HIV drug price cuts (IRA negotiation). Even before patents expire, net revenue per patient drops. Biktarvy’s 73% HIV share makes it a target.

Most likely: The patent cliff. Over a 3–5 year horizon, the business shifts from “moated cash cow” to “generic-addled biotech.”

💰 Valuation & Margin of Safety

• Intrinsic value estimate: $115.58 / share (DCF: 3.4% FCF growth, 10% discount, 3% terminal). But this assumes the patent cliff is somehow avoided – a heroic assumption.
• 25% margin of safety entry: $86.69 / share – still prices in gentle decline, not a revenue collapse.
• 50% margin of safety entry: $57.79 / share – Buffett’s ideal: a cigar butt with one more puff, but you must be willing to sell before the stub burns.
• Current price: (Not given, but GILD trades ~$90). At ~$90, you’re paying above the 25% safety zone and far above the 50% floor. The stock is fair-to-expensive given the structural threat.

Verdict: PASS

The moat is a rental, not an ownership – Biktarvy’s patent cliff is a permanent impairment that no DCF can finesse, and management has proven incapable of replacing it. Even at a 25% discount, the business lacks the compounding economics Berkshire demands. Let others chase the cigar butt.